Clinical Trial Update: Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the anti-CD20 antibody ofatumumab in combination with ICE chemotherapy for diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Arzerra (ofatumumab)
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: COMPLETED